Literature DB >> 5425274

The possible role of adenosine in the coronary dilator action of some pyrimidopyrimidines and pteridines.

M W Nott.   

Abstract

1. The abilities of some pyrimidopyrimidines (including dipyridamole) and pteridine derivatives to potentiate heart block produced by adenosine in the guinea-pig and to produce coronary dilatation in kitten hearts were investigated.2. The results demonstrated a correlation between adenosine potentiating and coronary dilating activities of the compounds studied, and are therefore compatible with the concept that compounds of the dipyridamole type owe their coronary dilator activity to potentiation of endogenous adenosine.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5425274      PMCID: PMC1702851          DOI: 10.1111/j.1476-5381.1970.tb12892.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  EXPERIMENTAL APPROACHES TO THE DEVELOPMENT OF ANTIANGINAL DRUGS.

Authors:  M M WINBURY
Journal:  Adv Pharmacol       Date:  1964

2.  [COMPETITIVE INHIBITION OF CATALYZED ADENOSINE DIFFUSION AS THE MECHANISM OF THE CORONARY DILATING EFFECT OF A PYRIMIDO-PYRIMIDINE DERIVATIVE].

Authors:  W KUEBLER; H J BRETSCHNEIDER
Journal:  Pflugers Arch Gesamte Physiol Menschen Tiere       Date:  1964-07-01

3.  [The elimination of adenosine from the blood under the influence of 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-(5,4-d) pyrimidine and papaverine].

Authors:  F W KOSS; G BEISENHERZ; R MAERKISCH
Journal:  Arzneimittelforschung       Date:  1962-11

4.  The potentiation of the action of adenosine on the guinea pig heart by ouabain.

Authors:  M RAND; A STAFFORD; R H THORP
Journal:  J Pharmacol Exp Ther       Date:  1955-05       Impact factor: 4.030

5.  The effect on the isolated rabbit heart of vagal stimulation and its modification by cocaine, hexamethonium and ouabain.

Authors:  L M MCEWEN
Journal:  J Physiol       Date:  1956-03-28       Impact factor: 5.182

6.  [Competitive inhibition of adenosine aminase as a possible cause of the coronary dilating effects of a pyrimidopyrimidine combination].

Authors:  B Deuticke; E Gerlach
Journal:  Naunyn Schmiedebergs Arch Pharmakol Exp Pathol       Date:  1966

7.  Effects of dipyridamole on contractions of the cat's nictitating membrane.

Authors:  W C Bowman; A Stafford
Journal:  Eur J Pharmacol       Date:  1968-05       Impact factor: 4.432

8.  Potentiation of adenosine and the adenine nucleotides by dipyridamole.

Authors:  A Stafford
Journal:  Br J Pharmacol Chemother       Date:  1966-11

9.  Effects of Persantin (RA8), a new coronary vasodilator, on coronary blood flow and cardiac dynamics in the dog.

Authors:  J W WEST; S BELLET; U C MANZOLI; O F MUELLER
Journal:  Circ Res       Date:  1962-01       Impact factor: 17.367

  9 in total
  5 in total

1.  A non-adrenergic inhibitory nervous pathway in guinea-pig trachea.

Authors:  R A Coleman; G P Levy
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

2.  Adenosine and dipyridamole actions and interactions on isolated coronary artery strips of cattle.

Authors:  S Kalsner
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

3.  Treatment of haemodynamic and electrocardiographic side-effects resulting from imipramine toxicity in rats and dogs.

Authors:  V B Fiedler; B Kettenbach; H Göbel; R E Nitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

4.  How does dipyridamole elevate extracellular adenosine concentration? Predictions from a three-compartment model of adenosine formation and inactivation.

Authors:  A C Newby
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

5.  Synthesis of Densely Functionalized Pyrimidouracils by Nickel(II)-Catalyzed Isocyanide Insertion.

Authors:  Jurriën W Collet; Bénédicte Morel; Hung-Chien Lin; Thomas R Roose; Pieter Mampuys; Romano V A Orru; Eelco Ruijter; Bert U W Maes
Journal:  Org Lett       Date:  2020-01-16       Impact factor: 6.005

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.